Equities analysts expect Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings of $0.30 per share for the current quarter, according to Zacks. Two analysts have made estimates for Dynavax Technologies Corporation’s earnings. The lowest EPS estimate is ($0.35) and the highest is $0.95. Dynavax Technologies Corporation reported earnings of ($0.56) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 153.6%. The firm is scheduled to announce its next quarterly earnings results on Monday, March 12th.
On average, analysts expect that Dynavax Technologies Corporation will report full year earnings of ($1.23) per share for the current year, with EPS estimates ranging from ($1.75) to ($0.25). For the next year, analysts expect that the business will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.26) to ($0.59). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Dynavax Technologies Corporation.
Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. The firm had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies Corporation had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The business’s quarterly revenue was down 68.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.90) earnings per share.
DVAX has been the subject of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $28.00 price target (up from $26.00) on shares of Dynavax Technologies Corporation in a research note on Monday, September 25th. Zacks Investment Research raised Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Cowen and Company reissued a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Friday, November 3rd. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their price target for the company from $6.00 to $27.00 in a research note on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Dynavax Technologies Corporation presently has a consensus rating of “Buy” and a consensus target price of $25.17.
COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies Corporation (DVAX) Expected to Announce Earnings of $0.30 Per Share” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://transcriptdaily.com/2017/11/15/dynavax-technologies-corporation-dvax-expected-to-announce-earnings-of-0-30-per-share.html.
Dynavax Technologies Corporation (DVAX) traded down $1.90 during midday trading on Tuesday, hitting $18.35. The stock had a trading volume of 4,069,700 shares, compared to its average volume of 1,889,366. Dynavax Technologies Corporation has a 1 year low of $3.20 and a 1 year high of $24.45.
A number of institutional investors have recently made changes to their positions in DVAX. PointState Capital LP bought a new position in Dynavax Technologies Corporation during the second quarter valued at approximately $13,510,000. Lord Abbett & CO. LLC bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at approximately $7,777,000. GMT Capital Corp lifted its stake in shares of Dynavax Technologies Corporation by 28.2% in the 2nd quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock valued at $29,450,000 after purchasing an additional 660,637 shares during the last quarter. Candriam Luxembourg S.C.A. bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at approximately $5,066,000. Finally, Bain Capital Public Equity Management LLC bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at approximately $4,741,000. 58.55% of the stock is owned by institutional investors.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.